Fludarabine-based versus CHOP-like regimens with or without rituximab in patients with previously untreated indolent lymphoma: a retrospective analysis of safety and efficacy

References

• SabattiniEBacciFSagramosoCPileriSAWHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overviewPathologica20101023838721171509
   PubMedGoogle Scholar
• JohnsonPWRohatinerAZWhelanJSPatterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single centerJ Clin Oncol19951311401477799014
   PubMed Web of Science ®Google Scholar
• MarcusRImrieKBelchACVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphomaBlood200510541417142315494430
   PubMed Web of Science ®Google Scholar
• HiddemannWKnebaMDreylingMFrontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood2005106123725373216123223
   PubMed Web of Science ®Google Scholar
• ForstpointnerRDreylingMReppRThe addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood2004104103064307115284112
   PubMed Web of Science ®Google Scholar
• KeatingMJO’BrienSAlbitarMEarly results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemiaJ Clin Oncol200523184079408815767648
   PubMed Web of Science ®Google Scholar
• TamCSWolfMPrinceHMFludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphomaCancer2006106112412242016649223
   PubMed Web of Science ®Google Scholar
• TamCSO’BrienSWierdaWLong-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemiaBlood2008112497598018411418
   PubMed Web of Science ®Google Scholar
• FerrarioAMerliFLuminariSPhase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL)Ann Hematol201190332333020848104
   PubMed Web of Science ®Google Scholar
• ZinzaniPLPulsoniAPerrottiAFludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphomaJ Clin Oncol200422132654266115159414
   PubMed Web of Science ®Google Scholar
• HagenbeekAEghbaliHMonfardiniSPhase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin’s lymphomaJ Clin Oncol200624101590159616575010
   PubMed Web of Science ®Google Scholar
• LeporrierMChevretSCazinBRandomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patientsBlood20019882319232511588025
   PubMed Web of Science ®Google Scholar
• FedericoMLuminariSDondiAR-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana LinfomiJ Clin Oncol201331121506151323530110
   PubMed Web of Science ®Google Scholar
• TsimberidouAMYounesARomagueraJImmunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimenCancer2005104234535315948158
   PubMed Web of Science ®Google Scholar
• McLaughlinPEsteyEGlassmanAMyelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alphaBlood2005105124573457515741224
   PubMed Web of Science ®Google Scholar
• HarrisNLJaffeESDieboldJWorld Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997J Clin Oncol199917123835384910577857
   PubMed Web of Science ®Google Scholar
• CarbonePPKaplanHSMusshoffKSmithersDWTubianaMReport of the Committee on Hodgkin’s Disease Staging ClassificationCancer Res19713111186018615121694
   PubMed Web of Science ®Google Scholar
• KarmaliRKassarMVenugopalPSafety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphomaClin Lymphoma Myeloma Leuk201111646747421700527
   PubMed Web of Science ®Google Scholar
• SharmaRCunninghamDSmithPInflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients – analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBOBMC Cancer2009915319450285
   PubMed Web of Science ®Google Scholar
• VoogEBienvenuJWarzochaKFactors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumor necrosis factor ligand-receptor systemJ Clin Oncol200018232533110637246
   PubMed Web of Science ®Google Scholar
• TamCSWolfMMJanuszewiczEHA new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignanciesCancer200410192042204915372472
   PubMed Web of Science ®Google Scholar
• MorrisonVARaiKRPetersonBLImpact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011J Clin Oncol200119163611362111504743
   PubMed Web of Science ®Google Scholar
• AvilésANeriNHuerta-GuzmánJde Jesús NamboMESHAP versus rituximab-ESHAP in frail patients with refractory diffuse large B-cell lymphomaClin Lymphoma Myeloma Leuk201010212512820371445
   PubMed Web of Science ®Google Scholar
• EveHELinchDQianWToxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II studyLeuk Lymphoma200950221121519197729
   PubMed Web of Science ®Google Scholar
• LaniniSMolloyACFinePEPrenticeAgIppolitoGKibblerCCRisk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysisBMC Med201193621481281
   PubMed Web of Science ®Google Scholar
• RaananiPGafter-GviliAPaulMBen-BassatILeiboviciLShpilbergOImmunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysisLeuk Lymphoma200950576477219330654
   PubMed Web of Science ®Google Scholar
• KasamonYLFlinnIWGreverMRPhase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemiaClin Cancer Res200511238413841716322303
   PubMed Web of Science ®Google Scholar
• EltingLSLuCEscalanteCPOutcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropeniaJ Clin Oncol200826460661118235119
   PubMed Web of Science ®Google Scholar
• GruberMFleissKPorpaczyEProlonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximabAnn Hematol201190101131113621617923
   PubMed Web of Science ®Google Scholar